JSPR

TentativeAI MemoPost-earnings T+3

Jasper Therapeutics

As of 2026-05-16/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-16 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

Phase 2b CSU start is the key upside event but is funding-dependent • 2026-08-14

Expected move: -22%

Biggest risk

The immediate bear case strengthened after earnings because the company paired the protocol update with an explicit going-concern warning and a stated need for additional capital; visible sell-side reaction appears more cautious, but thin coverage means analyst changes should be treated as secondary to the primary-source financing and runway disclosures.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

Post-earnings, the core bullish view is that briquilimab still has clinically supportive CSU data and a refilled Phase 2b protocol, so a successful financing that enables a second-half 2026 study start could reopen the path to a larger clinical re-rating from a depressed base.

Research note

Recommendation

—

Confidence

medium

As of

2026-05-16

Base target

p=45%

Bull target

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Near-term financing decision dominates the setup
Briquilimab CSU dataset supports dose selection but still needs execution capital
Post-earnings, the core bullish view is that briquilimab still has clinically supportive CSU data and a refilled Phase 2b protocol, so a successful financing that enables a second-half 2026 study start could reopen the path to a larger clinical re-rating from a depressed base.

BearKey bullets

Competitive pressure in mast-cell diseases remains relevant, including KIT-based programs identified in Jasper's 10-K; the available peer read-through is direct scientifically but weak for valuation comparison [#10-K-2026-03-30].
Going-concern disclosure and explicit near-term funding need [#10-Q-2026-05-14].
If financing is unavailable or expensive, Jasper may delay, reduce, or eliminate research programs [#10-Q-2026-05-14].

WatchKey bullets

Phase 2b CSU start is the key upside event but is funding-dependent

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $1 (p=45%)

Bull/Bear spread: +66% / -67%

Vs latest close: Bull +66% · Base -22% · Bear -67%

Scenario probabilities

Bull Target: $2 (p=25%)Base Target: $1 (p=45%)Bear Target: $0 (p=30%)

Commentary

This was a T+3 earnings follow-up with meaningful primary-source confirmation. The immediate market reaction was negative: JSPR closed at $0.9590 on May 14, 2026 and $0.8501 on May 15, 2026, an about 11.4% drop day over day. Post-print tone is cautious, but coverage is thin, analyst-target data appear stale, and the cleanest peers are direct clinical competitors rather than valuation comps. Net takeaway: sentiment is cautious and event-driven rather than capitulation-proof, and missing a financing update remains the main reason to keep confidence moderate-to-low.

As of 2026-05-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Near-term financing decision dominates the setup
Briquilimab CSU dataset supports dose selection but still needs execution capital

Scenarios

Bull Target (Scenario probability)

$2 / p=25% prob

Base Target (Scenario probability)

$1 / p=45% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Price $1 as of 2026-05-27

Nearest Scenario: Base (∆ 22%)

Targets vs latest close: Bull +66% · Base -22% · Bear -67%

Sentiment & Exposure

News Sentiment (30d)

-0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-08-14
Phase 2b CSU start is the key upside event but is funding-dependent
The May 14, 2026 earnings update said Jasper refiled an updated Phase 2b protocol with the FDA and is working to secure funding to start the CSU Phase 2b study in the second half of 2026 [#8-K-2026-05-14].
Prob 45.00% • Move 55.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

Near-term financing decision dominates the setup
2026-06-30
Jasper ended Q1 2026 with $14.1M of cash and cash equivalents, disclosed substantial doubt about its ability to continue as a going concern, and said it is actively seeking additional capital to extend runway; failure to fund would likely force broader R&D cuts or delays [#10-Q-2026-05-14].
Prob 80% • Move -30% • Priced-in 75%

Long-term Catalysts

Months to a year

Briquilimab CSU dataset supports dose selection but still needs execution capital
2026-12-31
Management said full BEACON, SPOTLIGHT, and open-label extension analysis supported selection of two active dosing regimens, and the January CSU update remained positive, but the path from encouraging data to value realization now depends on financing and trial execution [#8-K-2026-05-14].
Prob 40% • Move 70% • Priced-in 30%

Risks

Competitive pressure in mast-cell diseases remains relevant, including KIT-based programs identified in Jasper's 10-K; the available peer read-through is direct scientifically but weak for valuation comparison [#10-K-2026-03-30].
Going-concern disclosure and explicit near-term funding need [#10-Q-2026-05-14].
If financing is unavailable or expensive, Jasper may delay, reduce, or eliminate research programs [#10-Q-2026-05-14].
Phase 2b CSU start is contingent on raising capital despite the protocol refiling [#8-K-2026-05-14].
Thin coverage and micro-cap biotech volatility can amplify downside around any financing, protocol, or trial-timing update.

Peers

Symbol	Summary
CLDX	Celldex is the most relevant direct operating peer because Jasper's 10-K identifies it as developing a KIT antibody in mast-cell diseases; this is useful for clinical and sentiment read-through, but Celldex is not a clean valuation comp for Jasper's distressed micro-cap financing setup [#10-K-2026-03-30].

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-16

AI Stock Memo: JSPR - Jasper Therapeutics - RankAlpha